Michael Sailor
Founder at Impilo Therapeutics, Inc.
Profile
Michael Sailor is the founder of Impilo Therapeutics, Inc. He currently holds a position as Director at Cend Therapeutics, Inc.
Michael Sailor active positions
Companies | Position | Start |
---|---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Founder | - |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Director/Board Member | 2020-09-20 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Technology Services |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Michael Sailor